BR112012008193A2 - composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor - Google Patents

composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor

Info

Publication number
BR112012008193A2
BR112012008193A2 BR112012008193A BR112012008193A BR112012008193A2 BR 112012008193 A2 BR112012008193 A2 BR 112012008193A2 BR 112012008193 A BR112012008193 A BR 112012008193A BR 112012008193 A BR112012008193 A BR 112012008193A BR 112012008193 A2 BR112012008193 A2 BR 112012008193A2
Authority
BR
Brazil
Prior art keywords
compositions
inhibitor
disease
well
methods
Prior art date
Application number
BR112012008193A
Other languages
English (en)
Inventor
Philip Seeman
Original Assignee
Clera Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clera Inc filed Critical Clera Inc
Publication of BR112012008193A2 publication Critical patent/BR112012008193A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composições e métodos para tratamento de doença de parkinson. esta invenção descreve composições de inibidores de receptores, incluindo agentes antipsicóticos típicos, por exemplo, haloperidol, e métodos de uso para tratamento de sinais cilíndricos ou sintomas de doença de parkinson. além disso, esta invenção descreve composições e métodos de induzir supersensibilidade em dopamina d2 e outros receptores envolvidos em doença de prakinson como um meio de aliviar os sinais clínicos ou sintomas de doença de parkinson.
BR112012008193A 2009-07-31 2010-07-30 composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor BR112012008193A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23026409P 2009-07-31 2009-07-31
PCT/CA2010/001185 WO2011011886A1 (en) 2009-07-31 2010-07-30 Compositions and methods for treating parkinson's disease

Publications (1)

Publication Number Publication Date
BR112012008193A2 true BR112012008193A2 (pt) 2016-03-01

Family

ID=43528672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008193A BR112012008193A2 (pt) 2009-07-31 2010-07-30 composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor

Country Status (12)

Country Link
US (1) US9192605B2 (pt)
EP (1) EP2459194A4 (pt)
JP (1) JP5756105B2 (pt)
KR (1) KR20120103557A (pt)
CN (1) CN102548555A (pt)
AU (1) AU2010278645A1 (pt)
BR (1) BR112012008193A2 (pt)
CA (1) CA2769149A1 (pt)
IL (1) IL217149A0 (pt)
MX (1) MX2012001290A (pt)
NZ (1) NZ598247A (pt)
WO (1) WO2011011886A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104884064A (zh) 2012-12-24 2015-09-02 纽洛佳斯特拉斯公司 用于治疗胃肠道病症的方法
JP6371716B2 (ja) * 2014-04-01 2018-08-08 東京エレクトロン株式会社 基板液処理装置及び基板液処理方法並びに基板液処理プログラムを記録したコンピュータ読み取り可能な記録媒体
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма
US20010056101A1 (en) * 1998-06-29 2001-12-27 Carol A. Tamminga Use of dopamine receptor antagonists in combination with partial dopamine agonist to prevent tolerance in treating nervous disorders related to dopamine dysfunction
DE10111486A1 (de) 2001-03-09 2002-10-02 Ralph R Dawirs Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit
WO2004026299A1 (en) 2002-09-17 2004-04-01 Motac Neuroscience Limited Treatment of dyskinesia
JP2006505589A (ja) 2002-10-22 2006-02-16 ドラッグアビューズ サイエンシズ エス．アー．エス． 選択的ドーパミンｄ１受容体アゴニストを使用した認知障害の治療法
CA2628298A1 (en) 2004-11-03 2006-05-11 Clera Inc. Method to detect dopamine receptors in the functional d2high state
CA2712800A1 (en) * 2008-02-05 2009-08-13 Clera Inc. Compositions and methods for alleviating depression or improving cognition

Also Published As

Publication number Publication date
US9192605B2 (en) 2015-11-24
CA2769149A1 (en) 2011-02-03
JP5756105B2 (ja) 2015-07-29
KR20120103557A (ko) 2012-09-19
EP2459194A1 (en) 2012-06-06
WO2011011886A1 (en) 2011-02-03
MX2012001290A (es) 2012-06-12
CN102548555A (zh) 2012-07-04
JP2013500943A (ja) 2013-01-10
EP2459194A4 (en) 2012-12-19
IL217149A0 (en) 2012-02-29
NZ598247A (en) 2014-01-31
US20120115910A1 (en) 2012-05-10
AU2010278645A1 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
CY1120741T1 (el) Θεραπεια οζωδους σκληρυνσης
ES2570332T3 (es) La combinación de anticolinérgicos y antagonistas del receptor de leucotrieno para el tratamiento de enfermedades respiratorias
BRPI1013777A8 (pt) Compostos agonistas do receptor 5-ht4 para tratamento de distúrbios cognitivos.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
GT200800250A (es) Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina
ECSP10010390A (es) Compuestos
CR10309A (es) "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1"
DOP2013000036A (es) Derivados de ciclobutano como inhibidores de jak
UY30829A1 (es) Compuestos agonistas y antagonistas del receptor de esfinfosina-1-fosfato
CL2011002056A1 (es) Compuestos derivados del acido {7-([1,2,3]triazol-1-il)-6,7,8,9-tetrahidropirido[1,2-a]indol-10-il}-acetico, antagonista del receptor crth2; composicion farmaceutica que lo comprende; utiles ene l tratamiento del asma, alergias, cancer entre otras.
ECSP088835A (es) Terapia combinatoria que involucra antagonistas de alfa5beta1
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
NI201100084A (es) Antagonistas del receptor de orexina de isonicotinamida.
CR20110100A (es) Nuevos derivados de sulfamida sustituida
BRPI1015006A2 (pt) uso tópico, periocular, ou intraocular de tocotrienóis para o tratamento de doenças oftálmicas
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
BRPI0912362A2 (pt) antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
CL2008003549A1 (es) Compuestos derivados de glucocorticoides; procedimientos de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades a la piel como eczema, afecciones a la nariz, garganta y pulmones como rinitis o asma, enfermedades inflamatorias del intestino, oculares y autoinmunes.
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
NO20085099L (no) Puritonderivativer som HM74A agonister
BRPI0919231A2 (pt) agonista de receptor de neuropeptídeo-2, composição farmacêutica que o compreende, seu uso e método para o tratamento ou profilaxia de enfermidades
BR112013009004A2 (pt) combinações de agonistas de receptor de serotonina para o tratamento de distúrbios de movimento
BR112012008193A2 (pt) composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor
CL2008002450A1 (es) Compuestos derivados de fenil-pirrolidin-eter, con actividad antagonista de los receptores nk3; procedimientos para su preparacion; composicion farmaceutica; y el uso de los compuestos en el tratamiento de depresion, dolor, psicosis, entre otras.
CL2008002808A1 (es) Compuestos derivados de benzoxazol, agonistas del receptor muscarinico m1; composicion farmaceutica que comprende a dichos compuestos; y uso para el tratamiento de esquizofrenia, alteraciones cognitivas o enfermedad de alzheimer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]